US 11,884,722 B2
Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof
Ricardo Attar, Lawrenceville, NJ (US); Francois Gaudet, Spring House, PA (US); Mark Tornetta, Collegeville, PA (US); Alexey Teplyakov, Phoenixville, PA (US); Mark Mendonca, Philadelphia, PA (US); Suzanne Edavettal, San Diego, CA (US); Kodandaram Pillarisetti, Spring House, PA (US); Nathan Majewski, Warrington, PA (US); Yingzhe Li, Dresher, PA (US); Leopoldo L. Luistro, III, Lansdale, PA (US); and Diana Chin, Norwood, PA (US)
Assigned to JANSSEN BIOTECH, INC., Horsham, PA (US)
Filed by Janssen Biotech, Inc., Horsham, PA (US)
Filed on Jan. 20, 2023, as Appl. No. 18/157,800.
Application 16/779,713 is a division of application No. 15/655,086, filed on Jul. 20, 2017, granted, now 10,562,968, issued on Feb. 18, 2020.
Application 18/157,800 is a continuation of application No. 16/779,713, filed on Feb. 3, 2020, granted, now 11,685,777.
Claims priority of provisional application 62/364,811, filed on Jul. 20, 2016.
Prior Publication US 2023/0227548 A1, Jul. 20, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/28 (2013.01) [A61K 39/0011 (2013.01); C07K 16/2809 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 25 Claims
 
1. An isolated GPRC5D×CD3 bispecific antibody comprising:
a) a first heavy chain (HC1);
b) a second heavy chain (HC2);
c) a first light chain (LC1); and
d) a second light chain (LC2),
wherein the HC 1 and the LC 1 pair to form a first antigen-binding site that specifically binds CD3, and the HC2 and the LC2 pair to form a second antigen-binding site that specifically binds GPRC5D; wherein the HC1 comprises the amino acid sequence of SEQ ID NO: 99, and the LC1 comprises the amino acid sequence of SEQ ID NO: 100, wherein the HC2 comprises the amino acid sequence of SEQ ID NO: 55, and the LC2 comprises the amino acid sequence of SEQ ID NO: 58.